Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) PT at $23.00

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have been given a consensus recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $23.00.

Several brokerages have issued reports on STOK. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, March 18th.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 over the last 90 days. 11.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS bought a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. bought a new stake in Stoke Therapeutics during the fourth quarter worth $124,000. Tower Research Capital LLC TRC lifted its stake in Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. acquired a new stake in Stoke Therapeutics in the fourth quarter valued at $133,000.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK opened at $8.29 on Friday. The company has a 50 day moving average price of $9.46 and a two-hundred day moving average price of $11.35. The company has a market capitalization of $448.31 million, a PE ratio of -3.95 and a beta of 0.99. Stoke Therapeutics has a 52 week low of $6.29 and a 52 week high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The business had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, sell-side analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.